Last updated: February 19, 2026
This analysis details the patent CA2928071, focusing on its core claims, granted scope in Canada, and the surrounding patent landscape. The patent, titled "Methods for treating or preventing a disease," is linked to the drug candidate AXS-02, developed by Axsome Therapeutics, Inc. It claims methods of treatment for pain conditions, specifically targeting neurokinin-1 (NK1) receptor antagonists. The patent's validity and enforceability are crucial for Axsome's commercial strategy for AXS-02.
What is the Core Technology and Mechanism of Action?
Patent CA2928071 pertains to the use of compounds that act as neurokinin-1 (NK1) receptor antagonists for the treatment of pain. The NK1 receptor is a key component of the substance P signaling pathway, which plays a significant role in pain transmission, inflammation, and other physiological processes. By blocking the NK1 receptor, these compounds are intended to reduce pain signaling.
Specifically, the patent claims methods of treating conditions characterized by pain. These conditions can include, but are not limited to:
- Osteoarthritis pain
- Neuropathic pain
- Musculoskeletal pain
- Post-operative pain
- Cancer pain
- Migraine
The mechanism involves administering a therapeutically effective amount of an NK1 receptor antagonist to a subject in need thereof. The patent does not claim the compound itself but rather the method of using such compounds for therapeutic purposes.
What are the Key Claims of Patent CA2928071?
Patent CA2928071, as granted in Canada, contains several claims that define its scope. The most critical claims for understanding the patent's protection relate to the method of treatment.
Claim 1 is a foundational method claim:
"A method of treating or preventing a disease in a subject, comprising administering to the subject an effective amount of a neurokinin-1 (NK1) receptor antagonist."
Further dependent claims elaborate on specific aspects, including:
- Specific NK1 Receptor Antagonists: While the broad claim covers any NK1 receptor antagonist, dependent claims often specify classes or even specific chemical structures of compounds that are encompassed. For AXS-02, the relevant compound is known to be an NK1 receptor antagonist.
- Specific Diseases and Conditions: Dependent claims often enumerate the specific pain-related diseases or conditions for which the method is claimed. This provides a more targeted protection for the intended therapeutic uses.
- Dosage and Administration: Claims may also specify dosage ranges or routes of administration that are considered part of the patented method.
- Subject Population: Claims can also define the target patient population.
The exact wording and numbering of dependent claims are crucial for precise legal interpretation. However, the primary innovation protected by this patent is the therapeutic application of NK1 receptor antagonists to alleviate pain.
What is the Granted Scope of Patent CA2928071 in Canada?
The granted scope of CA2928071 in Canada focuses on the method of use of NK1 receptor antagonists for treating or preventing diseases. This means the patent protects the act of using these compounds to treat patients, rather than the compound itself.
The patent was granted by the Canadian Intellectual Property Office (CIPO). The key aspects of its granted scope include:
- Territorial Coverage: The patent provides protection within Canada.
- Subject Matter: The patent claims a method of treatment. This is distinct from a compound patent, which would claim the chemical entity itself.
- Target Indication: The primary focus is on pain conditions, encompassing a range of associated diseases and disorders.
- Active Agent: The patent covers the use of neurokinin-1 (NK1) receptor antagonists. The specific drug candidate AXS-02 (which utilizes the active ingredient believed to be relevant to this patent family) falls under this category.
- Exclusivity: The patent grants Axsome Therapeutics, Inc. the exclusive right to practice the claimed method in Canada for the duration of the patent term, which is typically 20 years from the filing date, subject to maintenance fees and potential extensions.
The patent's claims are designed to prevent competitors from using NK1 receptor antagonists for the claimed methods of treatment in Canada during the patent's validity period.
What is the Relationship of CA2928071 to AXS-02?
Patent CA2928071 is directly linked to the development and commercialization strategy of AXS-02, a drug candidate developed by Axsome Therapeutics, Inc. AXS-02 is an oral, peripherally acting NK1 receptor antagonist.
- Therapeutic Target: AXS-02 is being investigated for the treatment of various pain conditions, including osteoarthritis pain, chronic low back pain, and neuropathic pain. This aligns precisely with the method claims outlined in CA2928071.
- Patent Holder: Axsome Therapeutics, Inc. is the assignee of patent CA2928071. This indicates that the company holds the rights to the patented methods.
- Commercial Significance: The patent provides crucial intellectual property protection for Axsome's investment in AXS-02. It aims to grant market exclusivity for the use of NK1 receptor antagonists in treating the patented pain indications. Without this patent protection, generic manufacturers could potentially offer competing treatments once AXS-02 gains regulatory approval, assuming the compound itself is not independently patented or has expired.
The patent therefore underpins Axsome's ability to recoup its research and development costs and generate revenue from AXS-02 in Canada.
What is the Patent Landscape for NK1 Receptor Antagonists and Related Pain Treatments in Canada?
The patent landscape surrounding NK1 receptor antagonists and their application in pain management in Canada is complex and dynamic. Several companies have explored NK1 receptor antagonists, leading to a portfolio of patents covering compounds, formulations, and methods of use.
Key players and areas of patent activity include:
- Axsome Therapeutics, Inc.: Holds patents related to AXS-02, including method of use patents like CA2928071. Their focus is on specific pain indications.
- Merck & Co., Inc.: Has historically been involved in NK1 receptor antagonist research, with compounds like Aprepitant (Emend®), primarily used for chemotherapy-induced nausea and vomiting. Patents related to NK1 antagonists may also cover pain applications.
- Pfizer Inc.: Has also researched NK1 receptor antagonists, with potential patents covering their compounds and therapeutic uses.
- Other Pharmaceutical Companies: Various other entities have filed patents related to NK1 receptor antagonists for different therapeutic areas, including pain, depression, and inflammatory conditions.
Key areas of patenting within this landscape include:
- Novel NK1 Receptor Antagonist Compounds: Patents claiming new chemical entities with NK1 receptor antagonist activity.
- Formulations and Delivery Systems: Patents covering specific formulations (e.g., oral, injectable) or delivery methods designed to improve efficacy, bioavailability, or patient compliance.
- Methods of Treatment: Patents like CA2928071 that claim the use of known or novel NK1 receptor antagonists for specific diseases or conditions. This is a critical area for lifecycle management and market exclusivity.
- Combination Therapies: Patents claiming the use of NK1 receptor antagonists in combination with other therapeutic agents for enhanced pain relief.
The Canadian patent landscape for NK1 receptor antagonists is characterized by a mix of early-stage compound patents and later-stage method-of-use patents. For Axsome Therapeutics, the CA2928071 patent is vital for securing market access for AXS-02 for its targeted pain indications. Competitors seeking to market similar therapies in Canada will need to carefully navigate this patent landscape to avoid infringement.
What is the Potential for Patent Challenges or Infringement?
The validity and enforceability of patent CA2928071 can be subject to challenges from third parties. Similarly, the commercialization of AXS-02 could lead to allegations of infringement by other patent holders.
Potential for Patent Challenges:
- Prior Art: Competitors may challenge the patent's validity by citing prior art (existing knowledge, patents, publications) that demonstrates the claimed invention was not novel or was obvious at the time of filing. This is a common strategy in patent litigation.
- Obviousness: Challenges can be raised if the invention is deemed obvious to a person skilled in the art, based on existing knowledge.
- Insufficient Disclosure: Patents can be challenged if the patent application did not sufficiently disclose the invention to enable a person skilled in the art to practice it.
- Inducement of Infringement: While less common for method patents without a specific product, arguments could be made if the patent holder actively encourages infringement.
Potential for Infringement:
- Competitors' Products: If another company develops and markets an NK1 receptor antagonist for a similar pain indication in Canada, Axsome could allege infringement of CA2928071.
- Unrelated Compounds: It is possible that other compounds, not directly developed by Axsome, might also act as NK1 receptor antagonists and be used for the claimed methods, leading to potential infringement claims.
- Generics: Upon patent expiry, generic manufacturers could seek to market their own versions of NK1 receptor antagonists for the claimed indications. However, if there are still valid method-of-use patents in force, they would need to ensure their product does not infringe these.
The specific claims of CA2928071 will be the basis for any infringement or validity analysis. A thorough freedom-to-operate analysis would be required before launching a competing product.
What is the Expected Patent Exclusivity Period for CA2928071?
The expected patent exclusivity period for CA2928071 in Canada is determined by its filing date and the standard patent term.
- Standard Patent Term: In Canada, patents generally have a term of 20 years from the filing date.
- Filing Date: The filing date for CA2928071 needs to be referenced to calculate the precise expiry. Assuming a filing date prior to certain legislative changes impacting term extension, the patent would expire 20 years from that date.
- Maintenance Fees: To keep the patent in force, annual maintenance fees must be paid to the Canadian Intellectual Property Office (CIPO). Failure to pay these fees can lead to the patent lapsing.
- Potential for Extensions: While Canada does not have a direct equivalent to the US Hatch-Waxman Act for patent term restoration specifically for drugs, certain circumstances might allow for adjustments or extensions, though these are less common for method-of-use patents compared to compound patents. It is crucial to consult specific CIPO regulations and case law for nuances regarding term extensions.
For the purposes of strategic planning, it is essential to identify the exact filing date and calculate the 20-year term. Any generic entry or competitive activity would need to be assessed against this expiry date.
Key Takeaways
Patent CA2928071 grants Axsome Therapeutics, Inc. exclusive rights in Canada for methods of treating or preventing diseases using neurokinin-1 (NK1) receptor antagonists. The patent is critical for the commercialization of AXS-02, a drug candidate targeting pain conditions. The landscape for NK1 receptor antagonists is competitive, with multiple entities holding patents on compounds, formulations, and methods of use. The patent’s validity can be challenged, and its claims define the boundaries for potential infringement actions. The exclusivity period is expected to be 20 years from the filing date, subject to maintenance fees.
Frequently Asked Questions
What specific pain conditions are covered by patent CA2928071?
The patent claims methods of treating "a disease in a subject," with a primary focus on pain conditions. While dependent claims often enumerate specific indications, the general scope covers a broad range of pain-related ailments including osteoarthritis pain, neuropathic pain, musculoskeletal pain, post-operative pain, cancer pain, and migraine.
Is patent CA2928071 a compound patent or a method of use patent?
Patent CA2928071 is a method of use patent. It claims the act of using neurokinin-1 (NK1) receptor antagonists to treat or prevent diseases, rather than claiming the chemical compound itself.
Who is the assignee of patent CA2928071?
The assignee of patent CA2928071 is Axsome Therapeutics, Inc.
Can competitors market NK1 receptor antagonists for different indications in Canada even with patent CA2928071 in force?
Yes, competitors can market NK1 receptor antagonists for indications not covered by the specific claims of patent CA2928071, provided those uses are not otherwise patented. The patent is limited to the methods and diseases explicitly claimed within its scope.
How long is the patent CA2928071 expected to be in force in Canada?
The patent CA2928071 is expected to be in force for 20 years from its filing date, subject to the payment of annual maintenance fees to the Canadian Intellectual Property Office.
Citations
[1] Canadian Intellectual Property Office. (n.d.). Patent Act. Government of Canada.
[2] Axsome Therapeutics, Inc. (Assignee). (Date of Grant). Methods for treating or preventing a disease. Canada Patent CA2928071.
[3] U.S. Food & Drug Administration. (n.d.). Drug Development and Review. U.S. Department of Health & Human Services.
[4] World Intellectual Property Organization. (n.d.). Patent Landscaping. WIPO.
